stockrowBio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) EV/EBITDA
Bio-Rad Laboratories, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 176× (September 2026) — the current reading is the lowest in ten years.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 172× | 431.33% |
| FY2024 | 32.4× | 22.36% |
| FY2023 | 26.5× | 11.66% |
| FY2022 | 23.7× | (42.63%) |
| FY2021 | 41.4× | 8.21% |
| FY2020 | 38.2× | (15.16%) |
| FY2019 | 45.1× | — |
| FY2018 | 0.0× | — |
| FY2017 | 29.9× | (0.39%) |
| FY2016 | 30.0× | 36.74% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 142× | 14.18% |
| Mar 2026 | 124× | (28.06%) |
| Dec 2025 | 172× | 418.96% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | n/m |
| GKOS Glaukos Corporation compare | n/m |
| TXG 10x Genomics compare | n/m |
| BIO.B Bio-Rad Laboratories, Inc. | n/m |
| SNN Smith & Nephew SNATS, Inc. compare | 6.5× |
| GMED Globus Medical, Inc. compare | 11.9× |
| PODD Insulet Corporation compare | 16.1× |
| PEN Penumbra, Inc. compare | 57.3× |
| BRKR Bruker Corporation compare | 66.0× |
| Medical Devices industry median | 11.5× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement